Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Case Report

Published on 11 Jul 2023

Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment

in Cancer Molecular Targets and Therapeutics

Xinyi Shao
Jin Yin
Di Wang
Erjiong Huang
Yini Zhang
Jiani C. Yin
Chen Huang
Hao Wu
Xiaoli Wu

Frontiers in Oncology

doi 10.3389/fonc.2023.1195837

2,006 views
1 citation

Brief Research Report

Published on 10 Jul 2023

MACC1 and MET as markers associated with progression and metastasis in cutaneous melanoma

in Cancer Molecular Targets and Therapeutics

Yan Zhou
Cody J. Rasner
Alessio Giubellino

Frontiers in Oncology

doi 10.3389/fonc.2023.1146092

1,466 views
1 citation

Editorial

Published on 07 Jul 2023

Editorial: Women in cancer molecular targets and therapeutics, volume II: 2022

in Cancer Molecular Targets and Therapeutics

Ioana Berindan-Neagoe
Cinzia Lanzi

Frontiers in Oncology

doi 10.3389/fonc.2023.1241793

1,435 views

Original Research

Published on 07 Jul 2023

Cystathionine β-synthase affects organization of cytoskeleton and modulates carcinogenesis in colorectal carcinoma cells

in Cancer Molecular Targets and Therapeutics

Veronika Liskova
Barbora Chovancova
Petr Babula
Ingeborg Rezuchova
Kristina Ploth Pavlov
Miroslava Matuskova
Olga Krizanova

Frontiers in Oncology

doi 10.3389/fonc.2023.1178021

2,942 views
2 citations

Editorial

Published on 07 Jul 2023

Editorial: Patient-derived tumor models for drug development

in Cancer Molecular Targets and Therapeutics

Hatim E. Sabaawy
Massimo Broggini
Shiv K. Gupta

Frontiers in Oncology

doi 10.3389/fonc.2023.1243534

1,951 views
1 citation

Original Research

Published on 05 Jul 2023

Yes-associated protein-1 overexpression in ocular surface squamous neoplasia; a potential diagnostic marker and therapeutic target

in Cancer Molecular Targets and Therapeutics

Peter Julius
Stepfanie N. Siyumbwa
Fred Maate
Phyllis Moonga
Guobin Kang
Trevor Kaile
John T. West
Charles Wood
Peter C. Angeletti

Frontiers in Oncology

doi 10.3389/fonc.2023.1213426

3,730 views
7 citations

Original Research

Published on 04 Jul 2023

Manipulating RKIP reverses the metastatic potential of breast cancer cells

in Cancer Molecular Targets and Therapeutics

Trang Huyen Lai
Mahmoud Ahmed
Jin Seok Hwang
Md Entaz Bahar
Trang Minh Pham
Jinsung Yang
Wanil Kim
Rizi Firman Maulidi
Dong-Kun Lee
Dong-Hee Kim

Frontiers in Oncology

doi 10.3389/fonc.2023.1189350

2,058 views
3 citations

Brief Research Report

Published on 03 Jul 2023

Genomic determinants in advanced endometrial cancer patients with sustained response to hormonal therapy- case series and review of literature

in Cancer Molecular Targets and Therapeutics

Divya Chukkalore
Anisha Rajavel
Divya Asti
Meekoo Dhar

Frontiers in Oncology

doi 10.3389/fonc.2023.1188028

2,347 views
2 citations

Review

Published on 03 Jul 2023

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions

in Cancer Molecular Targets and Therapeutics

David A. Russler-Germain
Armin Ghobadi

Frontiers in Oncology

doi 10.3389/fonc.2023.1168622

10,412 views
9 citations

Review

Published on 30 Jun 2023

Paper-based biosensors as point-of-care diagnostic devices for the detection of cancers: a review of innovative techniques and clinical applications

in Cancer Molecular Targets and Therapeutics

Mehrdad Mahmoodpour
Bahman Abedi Kiasari
Merat Karimi
Arezou Abroshan
Danial Shamshirian
Hamed Hosseinalizadeh
Alireza Delavari
Hamed Mirzei

Frontiers in Oncology

doi 10.3389/fonc.2023.1131435

5,901 views
12 citations

Correction

Published on 27 Jun 2023

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

in Cancer Molecular Targets and Therapeutics

Yulong Fu
Anqi Wang
Jieqi Zhou
Wei Feng
Minhua Shi
Xiao Xu
Hongqing Zhao
Liming Cai
Jian Feng
Xuedong Lv

Frontiers in Oncology

doi 10.3389/fonc.2023.1236311

1,451 views

Correction

Published on 27 Jun 2023

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer

in Cancer Molecular Targets and Therapeutics

Wei-Wei Zuo
Chun-Fang Zhao
Yan Li
Hai-Yan Sun
Guo-Ming Ma
Yue-Ping Liu
Shan Kang

Frontiers in Oncology

doi 10.3389/fonc.2023.1218746

1,081 views

Original Research

Published on 23 Jun 2023

An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma

in Cancer Molecular Targets and Therapeutics

Dong Zhang
Xi Zhang
Zhanpeng Liu
Tian Han
Kai Zhao
Xinchi Xu
Xu Zhang
Xiaohan Ren
Chao Qin

Frontiers in Oncology

doi 10.3389/fonc.2023.1207068

5,132 views
17 citations

Review

Published on 23 Jun 2023

Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy

in Cancer Molecular Targets and Therapeutics

Yuting Jia
Bin Guo
Wenbin Zhang
Feng Wang
Yong Zhang
Quanmao Zhang
Erfeng Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1110207

7,939 views
11 citations

Mini Review

Published on 20 Jun 2023

Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy

in Cancer Molecular Targets and Therapeutics

Teng Tu
Hongying Zhang
Huanji Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1197502

4,216 views
5 citations

Original Research

Published on 19 Jun 2023

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

in Cancer Molecular Targets and Therapeutics

Jiuhui Xu
Chenglong Chen
Kunkun Sun
Qianyu Shi
Boyang Wang
Yi Huang
Tingting Ren
Xiaodong Tang

Frontiers in Oncology

doi 10.3389/fonc.2023.1192472

2,670 views
4 citations